130 related articles for article (PubMed ID: 36099584)
21. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
22. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
[TBL] [Abstract][Full Text] [Related]
23. Reeducating Tumor-Associated Macrophages Using CpG@Au Nanocomposites to Modulate Immunosuppressive Microenvironment for Improved Radio-Immunotherapy.
Cao Y; Ding S; Zeng L; Miao J; Wang K; Chen G; Li C; Zhou J; Bian XW; Tian G
ACS Appl Mater Interfaces; 2021 Nov; 13(45):53504-53518. PubMed ID: 34704726
[TBL] [Abstract][Full Text] [Related]
24. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
Gilboa E; Berezhnoy A; Schrand B
Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880
[TBL] [Abstract][Full Text] [Related]
25. Photothermal therapies to improve immune checkpoint blockade for cancer.
Balakrishnan PB; Sweeney EE; Ramanujam AS; Fernandes R
Int J Hyperthermia; 2020 Dec; 37(3):34-49. PubMed ID: 33426992
[TBL] [Abstract][Full Text] [Related]
26. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
27. Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy.
Joo KI; Jeong Y; Hwang SM; Shin M; Lee J; Sharma G; Lee H; Im SH; Cha HJ
Biomaterials; 2020 Dec; 263():120380. PubMed ID: 32942128
[TBL] [Abstract][Full Text] [Related]
28. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
Front Immunol; 2022; 13():872295. PubMed ID: 35634282
[TBL] [Abstract][Full Text] [Related]
30. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
31. Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade.
Zboralski D; Hoehlig K; Eulberg D; Frömming A; Vater A
Cancer Immunol Res; 2017 Nov; 5(11):950-956. PubMed ID: 28963140
[TBL] [Abstract][Full Text] [Related]
32. Photothermal therapy mediated by gold nanocages composed of anti-PDL1 and galunisertib for improved synergistic immunotherapy in colorectal cancer.
Wang S; Song Y; Cao K; Zhang L; Fang X; Chen F; Feng S; Yan F
Acta Biomater; 2021 Oct; 134():621-632. PubMed ID: 34329782
[TBL] [Abstract][Full Text] [Related]
33. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy.
He M; Yang T; Wang Y; Wang M; Chen X; Ding D; Zheng Y; Chen H
Adv Healthc Mater; 2021 May; 10(9):e2002104. PubMed ID: 33709564
[TBL] [Abstract][Full Text] [Related]
36. Immune lipoprotein nanostructures inspired relay drug delivery for amplifying antitumor efficiency.
Han Y; Ding B; Zhao Z; Zhang H; Sun B; Zhao Y; Jiang L; Zhou J; Ding Y
Biomaterials; 2018 Dec; 185():205-218. PubMed ID: 30245388
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
38. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
39. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Development of Immune Checkpoint Inhibitors.
Wang J; Yang T; Xu J
Adv Exp Med Biol; 2020; 1248():619-649. PubMed ID: 32185726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
